Special Drug Use Investigation for PAXIL Tablet (Pediatric Panic Disorder)

NCT01376128 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 96

Last updated 2017-05-22

No results posted yet for this study

Summary

The objectives of this survey was to retrospectively collect and evaluate the information on the efficacy and safety of PAXIL tablets ("PAXIL", hereinafter) in pediatric subjects (aged under 18) with panic disorder under conditions of actual use.

Conditions

  • Panic Disorder

Interventions

DRUG

Paroxetine

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Eligibility

Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2009-02-28
Completion
2009-05-31

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01376128 on ClinicalTrials.gov